Business Context and Reporting Period
This Form 8-K was filed by NanoVibronix, Inc. (trading symbol: NAOV) on September 23, 2022. The report discloses a material event under Item 7.01 (Regulation FD Disclosure) regarding a new commercial contract for the Company's Uroshield product.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory and commercial milestone rather than financial performance data.
Material Changes
The primary material change reported is the approval of NanoVibronix's Uroshield product for sale through the United Kingdom's National Health System (NHS) internal supply organization, NHS Supply Chain, via a new contract.
Outlook and Management Commentary
Management announced the NHS Supply Chain contract approval via a press release furnished as Exhibit 99.1. The Company explicitly stated it undertakes no obligation to update, supplement, or amend the materials attached to this report. No specific financial guidance or risk factors were detailed within the body of this specific filing.
Investor Verification Checklist
- Verify the terms and financial value of the new NHS Supply Chain contract in the attached press release (Exhibit 99.1).
- Confirm the commercial launch timeline for Uroshield within the UK market.
- Review the Company's most recent 10-K or 10-Q for baseline financial health, as this 8-K contains no financial statements.
- Monitor subsequent filings for updates on the contract's impact on revenue, as the Company disclaimed an obligation to update this specific disclosure.